Within the final week of December, whereas many of the U.S. was nonetheless in vacation mode, Novo Nordisk’s plant in North Carolina was working at full capability.
On Dec. 22, the U.S. Meals and Drug Administration (FDA) permitted the corporate’s oral model of Wegovy, making it the primary capsule of the favored GLP-1 medicines to get the inexperienced mild for weight reduction. Individuals who need to shed extra pounds and are prescribed Wegovy now have the choice of taking the pill day by day, versus injecting themselves with the drug as soon as per week. They’ll lose about the identical quantity of weight with both model: between 16% and 17% of their beginning physique weight.
The plant, simply outdoors of Raleigh, is working across the clock to supply bottles of capsules in 4 totally different doses. The bottles are sure for retail shops and on-line pharmacies and shall be accessible beginning on Jan. 5. “Weight problems has turn into a consumer-oriented illness,” stated Novo Nordisk’s CEO Mike Doustdar in an interview with TIME. “We’re embracing that.”
The corporate’s whole provide of the drug, from begin to end, shall be manufactured in North Carolina. Days earlier than the launch of Wegovy capsule, TIME visited the plant to look at how the primary Wegovy capsules are being produced, bottled, and packaged for sufferers.
All of it begins with yeast
Wegovy capsule begins with a fungus: particularly, the identical yeast used to make bread, referred to as Saccharomyces cerevisiae. However as a substitute of fermenting sugars or grains to make bread rise, the yeast cells are genetically engineered at Novo Nordisk’s facility in Clayton, North Carolina to supply a protein that undergoes fermentation in a number of four-story tall tanks, then a number of purification steps over a couple of month to supply semaglutide, a compound that mimics a human hormone that regulates urge for food by working within the reward middle of the mind. It might assist folks really feel full and scale back emotions of starvation.
Harvesting the principle ingredient
After the fermentation and purification course of, semaglutide types a beige paste with the consistency of pancake batter. In one of many few guide steps within the largely automated manufacturing, technicians scrape the paste from giant funnels and freeze it at -20°C, the place it retains for as much as 5 years. However given the recognition of Wegovy and the anticipated demand for the capsule, the corporate at present has a couple of month’s provide of semaglutide in its freezers.
Taking capsule type
Within the remaining step of the method, the paste is thawed and purified right into a liquid at a excessive temperature. That heated liquid is then spray-dried right into a fantastic white powder, just like the way in which snow-making machines flip scorching water into snow. That powder, collected in giant baggage from a funnel that extends by way of three flooring, is then pressed into Wegovy tablets.
A protracted path to the capsule
Whereas this semaglutide capsule is the primary to deal with weight problems, it isn’t the primary that Novo Nordisk has made. The corporate’s scientists first turned considering semaglutide as a diabetes remedy since it will possibly additionally assist management blood glucose, and its first semaglutide-based remedy, Ozempic, was permitted in 2017 for diabetes. Sufferers injected themselves as soon as per week to manage blood sugar, however to make taking the drug simpler, the corporate additionally developed a capsule type, referred to as Rybelsus, which the FDA permitted in 2019. Turning Ozempic into an oral capsule required discovering a method to defend the drug from the hostile atmosphere of the abdomen simply lengthy sufficient for it to be absorbed by the physique. “However with numerous these methods, it might trigger an excessive amount of permeability—so issues that shouldn’t be absorbed, like micro organism or different issues, had been absorbed,” says Andrea Traina, senior medical director for weight problems and liver well being at Novo Nordisk. The scientists in the end discovered a method to create a chemical buffer to protect the drug whereas it launched sufficient semaglutide to be efficient. Nonetheless, as a result of the capsule has to undergo the abdomen and digestive tract, it’s usually not as efficient because the injected Ozempic.
When diabetes sufferers seen they had been shedding pounds on semaglutide, Novo Nordisk and different firms started to check the compound for its potential results on weight problems. Research confirmed what these sufferers had been experiencing, and in 2021, the FDA permitted Novo Nordisk’s Wegovy to deal with weight problems. However folks nonetheless needed to inject themselves with the treatment to profit from its results. Growing the Wegovy capsule turned the following problem, and the identical hurdles the corporate confronted in growing Rybelsus remained. However this time, the researchers developed a proprietary fatty acid spinoff to raised navigate the troublesome atmosphere of the abdomen. “After you swallow the pill, it is available in contact with the abdomen lining and begins to dissolve and create a foamy microenvironment across the capsule,” says Traina. “Image an Alka-Seltzer pill dissolving in water.” The response briefly inhibits abdomen enzymes within the space from breaking down the drug, which supplies the semaglutide sufficient time to be absorbed. “The entire course of takes about half an hour,” she says, after which era “the microenvironment of the abdomen goes again to regular.” To maximise the capsule’s capability to soak up, folks taking it ought to swallow it very first thing within the morning on an empty abdomen with as much as half a glass of water with no meals, drinks, or different medicines for a minimum of half-hour, the corporate advises, so nothing will intervene with the capsule’s exercise.
Stiff competitors
Wegovy capsule shouldn’t be the one GLP-1 weight-loss capsule on the horizon. Eli Lilly, which makes the injectable GLP-1 medicine Mounjaro for diabetes and Zepbound for weight reduction (utilizing the energetic ingredient tirzepatide) has developed a capsule referred to as orforglipron. In December, the corporate launched optimistic information displaying its capsule may assist folks preserve weight reduction after utilizing injected types of GLP-1 medicine for greater than a yr and submitted a request to the FDA for approval. The company granted orforglipron a precedence voucher in November, which means the FDA will conduct an expedited overview in order that capsule can come to market a lot sooner than the everyday drug.
Novo Nordisk and Eli Lilly have been locked in a GLP-1 competitors for years. Some analysis has discovered that Lilly’s drug Zepbound results in better weight reduction—as much as 21% of physique weight—in comparison with 15% on Wegovy. “The distinction may be very largely linked to doses,” says Doustdar; the very best dose tirzepatide is bigger than that of semaglutide in Wegovy. For that purpose, Novo Nordisk is growing the next dose of Wegovy within the injectable type that produces comparable quantities of about 20% weight reduction. “We shall be bringing Wegovy-Plus into the market [in 2026] so it’s going to shut the hole with our competitor,” he says.
He additionally sees semaglutide as the corporate’s “secret sauce” that appears to supply numerous well being advantages. It’s the one GLP-1 drug that the FDA permits to assert on its label advantages forthat coronary heart illness and sure liver situations profit. Whereas latest analysis discovered that the compound didn’t sluggish Alzheimer’s illness, as many had hoped it might, the drug’s capability to cut back irritation may result in extra well being advantages in different metabolic ailments.
Doustdar, who was appointed to go Novo Nordisk final summer time as the corporate started dropping market share within the GLP-1 area to Eli Lilly, sees Wegovy capsule as a coup for the corporate—and a return to specializing in diabetes and weight problems. “This can be a large illness space. We’re speaking about two billion folks, and ultimately, somebody has to supply all of the doses for them. We’re sitting in the appropriate spot proper now [to do that], and nonetheless solely touching a fraction of the people who find themselves in want.”
Choices for the capsule
In coming weeks, Wegovy capsule shall be accessible in 4 doses: a starter dose of 1.5 mg, in addition to 4 mg, 9 mg, and 25 mg. As with injectable Wegovy, most sufferers will begin with the bottom dose and steadily ramp up their dosage over a interval of months till they attain the utmost dose, which they may proceed to keep up their new weight.
As the corporate and the White Home introduced in November, the starter dose will price $149 for a month’s provide for folks paying out-of-pocket and utilizing federal insurance policy. The subsequent-highest dose shall be $149 till April 2026, after which it’s going to enhance to $199 a month. The 2 highest doses will price $299 for a month’s price of capsules. Individuals with insurance policy that cowl the capsules could pay as little as $24 for a 30-day provide.
Doustdar says the White Home announcement was the results of a number of months of debate to succeed in a mutually agreeable value plan for the drug. “For us to have the ability to make any offers, it has to not be a zero-sum recreation, however a win-win scenario,” he says. “We wanted to clarify that the price of operations within the U.S. may be very totally different from the price of operations in Europe.”
“Alternatively, we additionally acknowledge that at greater costs, we won’t get entry to larger volumes,” he says—and with lots of of thousands and thousands of individuals world wide who may doubtlessly profit from a weight-loss drug, Doustdar hopes Wegovy capsule shall be extra handy, and accessible, for them.
